Arbutus Biopharma Statistics
Total Valuation
ABUS has a market cap or net worth of $646.02 million. The enterprise value is $552.94 million.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABUS has 191.70 million shares outstanding. The number of shares has increased by 8.75% in one year.
| Current Share Class | 191.70M |
| Shares Outstanding | 191.70M |
| Shares Change (YoY) | +8.75% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 51.96% |
| Float | 136.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.59 |
| Forward PS | 155.03 |
| PB Ratio | 7.78 |
| P/TBV Ratio | 7.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 35.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.53, with a Debt / Equity ratio of 0.06.
| Current Ratio | 20.53 |
| Quick Ratio | 19.76 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -384.81 |
Financial Efficiency
Return on equity (ROE) is -52.82% and return on invested capital (ROIC) is -25.39%.
| Return on Equity (ROE) | -52.82% |
| Return on Assets (ROA) | -21.01% |
| Return on Invested Capital (ROIC) | -25.39% |
| Return on Capital Employed (ROCE) | -45.04% |
| Revenue Per Employee | $350,364 |
| Profits Per Employee | -$1.23M |
| Employee Count | 44 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.91% in the last 52 weeks. The beta is 0.86, so ABUS's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -6.91% |
| 50-Day Moving Average | 3.32 |
| 200-Day Moving Average | 3.38 |
| Relative Strength Index (RSI) | 54.53 |
| Average Volume (20 Days) | 650,033 |
Short Selling Information
The latest short interest is 12.98 million, so 6.77% of the outstanding shares have been sold short.
| Short Interest | 12.98M |
| Short Previous Month | 13.64M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 9.51% |
| Short Ratio (days to cover) | 18.41 |
Income Statement
In the last 12 months, ABUS had revenue of $15.42 million and -$54.25 million in losses. Loss per share was -$0.29.
| Revenue | 15.42M |
| Gross Profit | -37.39M |
| Operating Income | -44.25M |
| Pretax Income | -77.09M |
| Net Income | -54.25M |
| EBITDA | -43.24M |
| EBIT | -44.25M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $98.09 million in cash and $5.00 million in debt, giving a net cash position of $93.09 million or $0.49 per share.
| Cash & Cash Equivalents | 98.09M |
| Total Debt | 5.00M |
| Net Cash | 93.09M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 82.98M |
| Book Value Per Share | 0.43 |
| Working Capital | 98.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$60.19 million and capital expenditures -$86,000, giving a free cash flow of -$60.28 million.
| Operating Cash Flow | -60.19M |
| Capital Expenditures | -86,000 |
| Free Cash Flow | -60.28M |
| FCF Per Share | -$0.31 |
Full Cash Flow StatementMargins
| Gross Margin | -242.54% |
| Operating Margin | -287.06% |
| Pretax Margin | -351.92% |
| Profit Margin | n/a |
| EBITDA Margin | -280.51% |
| EBIT Margin | -287.06% |
| FCF Margin | n/a |
Dividends & Yields
ABUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.75% |
| Shareholder Yield | -8.75% |
| Earnings Yield | -8.40% |
| FCF Yield | -9.33% |
Analyst Forecast
The average price target for ABUS is $5.67, which is 68.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.67 |
| Price Target Difference | 68.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABUS has an Altman Z-Score of 1.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.22 |
| Piotroski F-Score | 4 |